Results 251 to 260 of about 66,449 (275)

Topotecan and Gemcitabine in Platinum/Paclitaxel-Resistant Ovarian Cancer

Oncology, 2000
24 patients were enrolled into a phase I–II study conducted to determine the maximum tolerated doses of topotecan-gemcitabine in sequential combination and the response rate in platinum/paclitaxel resistant ovarian cancer patients. A total of 83 courses are evaluable, with a median number of three cycles administered per patients (range 2–7). Topotecan
S, Greggi, M G, Salerno, G, D'Agostino, G, Ferrandina, D, Lorusso, L, Manzione, S, Mancuso, G, Scambia   +7 more
openaire   +2 more sources

Targeting EGFR Activation to Overcome Gemcitabine Resistance in Cholangiocarcinoma

Anticancer Research
Chemotherapy resistance is an important problem in the treatment of patients with cholangiocarcinoma (CCA) who are not eligible for surgery. This study aimed to overcome gemcitabine (Gem) resistance in CCA by investigating and targeting Gem resistance-associated molecules.Three stable Gem-resistant CCA cell lines (CCA-GemR) were established by ...
Sonexai, Kidoikhammouan, Worachart, Lert-Itthiporn, Raksawan, Deenonpoe, Charupong, Saengboonmee, Sumalee, Obchoei, Sopit, Wongkham, Wunchana, Seubwai   +6 more
openaire   +2 more sources

Gemcitabine in Multi-Resistant Non-Hodgkin Lymphomas

Tumori Journal, 2004
Enric Carcereny, Mariano Provencio, Pilar Espaa   +2 more
openaire   +2 more sources

Gemcitabine-resistant pancreatic cancer: a second-line option

The Lancet, 2016
Helmut, Oettle, Thorsten, Lehmann
openaire   +2 more sources

Antibiotic resistance in the patient with cancer: Escalating challenges and paths forward

Ca-A Cancer Journal for Clinicians, 2021
Amila K Nanayakkara, Kevin Outterson
exaly  

Resistance to gemcitabine in a lymphoma cell line resistant to Fas-mediated apoptosis.

Anticancer research, 2004
The T-cell lymphoma cell line HuT78B1, selected for resistance to Fas-mediated apoptosis, resulted unexpectedly resistant to the apoptotic and cytotoxic effects of gemcitabine (dFdC). We investigated whether this resistance was due to the impairment of the Fas/Fas-ligand (FasL) system.dFdC effects were studied in HuT78B1 and in the parental Fas ...
MELI, Maria, TOLOMEO M, D'ALESSANDRO, Natale, GRIMAUDO, Stefania, NOTARBARTOLO DI VILLAROSA, Monica, PAPOFF G, RUBERTI G, RAUSA, Luciano, DUSONCHET, Luisa   +8 more
openaire   +4 more sources

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet, The, 2023
Makoto Ueno, Heinz-Josef Klümpen, Mohamed bouattour   +2 more
exaly  

Pancreatic Cancer Resistance to Gemcitabine

2019
P.S. Sushma, Ganji Purnachandra Nagaraju
openaire   +1 more source

Gemcitabine effects on tumor microenvironment of pancreatic ductal adenocarcinoma: Special focus on resistance mechanisms and metronomic therapies

Cancer Letters, 2023
Ganji Purnachandra Nagaraju
exaly  

Reverse intratumor bacteria-induced gemcitabine resistance with carbon nanozymes for enhanced tumor catalytic-chemo therapy

Nano Today, 2022
Juqun Xi, Lei Fan, Lizeng Gao
exaly